Current & historical transactions

IMPORTANT NOTICE

Access to the information and portion of the website to which this gatepost gives access is restricted for regulatory reasons. The information to which this gatepost gives access is exclusively intended for persons who are not residents of the United States and who are not physically present in the United States or certain other restricted jurisdictions. The information to which this gatepost gives access does not constitute an offer, or an invitation to purchase, securities of the Company in the United States, Australia, Canada, Hong Kong, Japan, New Zealand, South Africa or in any other jurisdiction in which such offer or invitation is not authorised or to any person to whom it is unlawful to make such offer or solicitation. Potential users of this information are requested to inform themselves about and to observe any such restrictions.

The Company’s securities cannot be offered or sold in the United States without registration under the United States Securities Act of 1933, as amended, or pursuant to an exemption from such registration. The Company has not registered, and does not intend to register, any of its securities under the Securities Act or to conduct a public offering of securities in the United States.

This page does not form part of an offer to sell securities in the United States. No offer is or will be made, directly or indirectly, in or into, nor may be accepted from, the United States or in any other jurisdiction in which such offer or invitation is not authorised.

By proceeding to view the materials to which this gatepost gives access, you warrant that: (i) you are not residents of the United States, you are not physically present in the United States and you are not residents of or physically present in any other jurisdiction in which such offer or invitation is not authorised; and (ii) it is lawful for you to receive the materials to which this gatepost gives access, and you agree that you will not transmit or otherwise send any information to which this gatepost gives access: (i) to any person in the United States or any other jurisdiction in which such offer or invitation is not authorised; or (ii) to publications with a general circulation in the United States or in any other jurisdiction in which such offer or invitation is not authorised.

Collaboration with and securing of certain commercial rights in the United States from AstraZeneca UK Limited (AZ) in respect of Tudorza® and Duaklir® and the issue of ordinary shares in Circassia Pharmaceuticals plc (the Company) to AZ as partial consideration (the Transaction).

By proceeding to view the materials to which this gatepost gives access, you acknowledge and agree that each of the materials for and in connection with: (i) the Company’s initial public offering in 2014; (ii) the placing and open offer in 2015; and (iii) the acquisitions of Aerocrine AB and Prosonix Limited in 2015 (the Historical Information) is current only as of its date and shall not, under any circumstances, create any implication that the information contained therein is correct as of any time subsequent to the date thereof or that there has been no change in the financial condition or affairs of the Company since such date. The Historical Information contained on the portion of the website to which this gatepost gives access is not provided for the purposes of making an investment decision. The Company has not given any undertaking to keep the Historical Information up to date or to post any amendments or supplements to the Historical Information on this website.

By proceeding to view the materials to which this gatepost gives access, you warrant that: (i) you will not rely upon the Historical Information when considering the Transaction or making an investment decision; and (ii) any considerations of and decisions made in respect of the Transaction shall be made solely on the basis of the information contained in the combined prospectus and circular published in connection with the Transaction, under the heading “2017 – Transaction relating to Tudorza® and Duaklir®”.

No representation or warranty (express or implied) is made as to, and no reliance for this Transaction may or should be placed by any person on, any information, including projections, estimates, targets and opinions, or the completeness, accuracy or fairness of such information contained in the Historical Information, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained in the Historical Information. Accordingly, neither the Company nor any of its officers or employees accepts any liability whatsoever arising directly or indirectly from the use of the Historical Information for this Transaction for any purpose whatsoever.

To continue, please select the country you are located in and indicate that you have read and agree to the above.

Please also ensure that you have both Javascript and cookies enabled in your web browser, or you will be unable to access the materials.